EVALUATION OF THE EFFICACY AND SAFETY OF FLUPIRTINE IN THE THERAPY OF ACUTE NONSPECIFIC LOW BACK PAIN
- Authors: Vyshlova I.1, Karpov S.1, Baida K.1
-
Affiliations:
- Stavropol State Medical University
- Issue: Vol 28, No 6 (2017)
- Pages: 45-47
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/116933
- ID: 116933
Cite item
Abstract
Flupirtine is a promising agent for the relief of pain of various origin. It has analgesic, muscle relaxant, and neuroprotective activities. The pharmacological properties of flupirtine allow it to be effectively used to treat low back pain, especially in patients with comorbidity. The analgesic activity and tolerability of flupirtine in the therapy of acute nonspecific low back pain in patients with comorbidity.
Keywords
Full Text
About the authors
I. Vyshlova
Stavropol State Medical UniversityCandidate of Medical Sciences
S. Karpov
Stavropol State Medical University
Email: Karpov25@rambler.ru
Professor MD
K. Baida
Stavropol State Medical UniversityCandidate of Medical Sciences
References
- Данилов А.Б., Николаева Н.С. Эффективность новой формы флупиртина (Катадолона форте) в лечении острой боли в спине // Manage pain. - 2013; 1: 44-8.
- Камчатнов П.Р., Батышева Т.Т., Ганжула П.А. и др. Применение катадолона у больных со спондилогенной дорсалгией // Журн. неврол. и психиат. -2006; 106 (11): 46-8.
- Каратеев А.Е. Что может стать альтернативой нестероидным противовоспалительным препаратам для контроля острой скелетно-мышечной боли у пациента, имевшего в анамнезе инфаркт миокарда и желудочно-кишечное кровотечение? // Consilium Medicum. (Прил. Неврология и ревматологи я).-2016; 1: 5-12.
- Левин Я.И., Стрыгин К.Н., Добровольская Л.Е. Катадолон в лечении боли в спине // Лечение нервных болезней. - 2005; 6 (3): 12-7.
- Эрдес Ш., Галушко Е., Зоткин Е. и др. Эффективность катадолона (флупиртина) у пациентов с болями в нижней части спины // Врач. - 2007; 5: 56-9.
- Brune K., Patrignani P. New insights into the use of currently available nonsteroidal anti-inflammatory drugs // J. Pain Res. - 2015; 20 (8): 105-18. doi: 10.2147/JPR.S75160.
- Klawe C., Maschke M. Flupirtine: pharmacology and clinical applications of a nonopioid analgesic and potentially neuroprotective compound // Exp. Opin. Pharmacother. - 2009; 10 (9): 1495-500.
- Mueller-Schwefe G. Flupirtine in acute and chronic pain associated with muscle tenseness: results of a postmarket surveillance study // Fortschr. Med. Orig. - 2003; 121 (1): 11-8.
- Murray C., Barber R., Foreman K. et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition // Lancet. - 2015; 386 (10009): 2145-91. doi: 10.1016/S0140-6736(15)61340-X.
- Raffa R., Pergolizzi Jr. J. The evolving understanding of the analgesic mechanism of action of flupirtine // J. Clin. Pharm. Ther. - 2012; 37: 4-6. doi: 10.1111/j.1365-2710.2010.01233.x
- Uberall M., Essner U., Müller-Schwefe G. 2-week efficacy and tolerability of flupirtine MR and diclofenac in patients with acute low/back pain-results of a post-hoc subgroup analysis of patient-level data from four non-interventional studies // MMW Fortschr Med. - 2013; 155 (Suppl. 4): 115-23.